药物基因组学领域药物经济学评价的问题探讨

Issues surrounding pharmacoeconomic evaluation of pharmacogenomics

药物基因组学已成为医学和药学研究与发展中的重要领域之一,国际上已越来越重视该领域的药物经济学研究,但中国尚未见相关研究。本文对该领域的药物经济学评价中需要注意的多个问题进行探讨,认为未来的药物基因组学筛查方案应基于良好的循证依据,其药物经济学分析应该严格按照相关的《药物经济学评价指南》执行,使用正确的方法,选择合适的研究角度,进行更广泛的敏感性分析,采用合理的分析时间和贴现率。

Pharmacogenomics has become an important focus in medical and pharmaceutical research and development.Pharmacoeconomic analyses of pharmacogenomics have attracted more attentions in the world,but have not been performed in China.In this paper,relevant remarkable problems are discussed in pharmacoeconomic field of pharmacogenomics.Future pharmacogenomics screening strategies should be good evidence-based.Pharmacoeconomic evaluation should be done in accordance with relevant pharmacoeconomics evaluation guidelines,including correct methods and suitable perspective,extensive sensitivity analyses,and rational time horizon and discounting rates.